IP – Page 11 – Pharma.Tips

Impurity profile drift detected during incoming testing – preventing batch rejection and recall

Addressing Impurity Profile Drift during Incoming Testing to Avoid Batch Disparities Encountering an impurity profile drift during incoming testing can trigger alarms within any pharmaceutical manufacturing facility. With stringent regulatory…

Residual solvent excursions during deviation investigation – preventing batch rejection and recall

Understanding Residual Solvent Excursions in Deviation Investigations to Prevent Batch Rejections In pharmaceutical manufacturing, the detection of residual solvent excursions can prompt significant concern, often leading to batch rejection or…

Impurity profile drift detected during stability studies – root cause investigation framework

Framework for Investigating Impurity Profile Drift Detected in Stability Studies In the world of pharmaceutical manufacturing, detecting an impurity profile drift during stability studies can trigger significant concerns regarding compliance,…

Particle size variability impacts performance during regulatory inspection – CAPA aligned to GMP expectations

Understanding How Particle Size Variability Affects Regulatory Performance In pharmaceutical manufacturing, maintaining consistent particle size of raw materials, especially Active Pharmaceutical Ingredients (APIs) and excipients, is critical for ensuring product…

Impurity profile drift detected during incoming testing – root cause investigation framework

Framework for Investigating Impurity Profile Drift Detected During Incoming Testing The detection of impurity profile drift during incoming testing poses a significant challenge for manufacturing and quality assurance teams within…

Residual solvent excursions during supplier change – preventing batch rejection and recall

Managing Residual Solvent Excursions During Supplier Change to Avoid Batch Rejection Manufacturers frequently face challenges related to residual solvent levels during supplier changes, threatening compliance with regulatory expectations and risking…

Residual solvent excursions during stability studies – root cause investigation framework

Framework for Investigating Residual Solvent Excursions in Stability Studies In the world of pharmaceutical manufacturing, excursions noted during stability studies can impinge on the integrity of active pharmaceutical ingredients (APIs)…

Residual solvent excursions during regulatory inspection – CAPA aligned to GMP expectations

Addressing Residual Solvent Excursions During Regulatory Inspections: A Comprehensive Investigation Framework Residual solvent excursions can pose significant challenges during regulatory inspections, often leading to non-compliance issues that may affect product…

API stability failure during stability studies – preventing batch rejection and recall

Investigating API Stability Failures During Stability Studies and Strategies for Prevention In the pharmaceutical industry, managing the stability of Active Pharmaceutical Ingredients (APIs) during stability studies is critical to ensuring…

API assay variability exceeds trend limits during supplier change – CAPA aligned to GMP expectations

Addressing Variability in API Assay During Supplier Transitions: A Structured Investigation Approach In the ever-evolving pharmaceutical landscape, maintaining the integrity of Active Pharmaceutical Ingredients (APIs) is critical, especially during supplier…

API stability failure during incoming testing – regulatory impact assessment

Assessing API Stability Failures During Incoming Testing: An Investigative Approach Pharmaceutical manufacturers often encounter challenges during incoming testing of active pharmaceutical ingredients (APIs), notably with stability failures that can impact…

API stability failure during stability studies – root cause investigation framework

Framework for Investigating API Stability Failures During Stability Studies API stability failures during stability studies can pose significant challenges for pharmaceutical manufacturers, affecting product release and regulatory compliance. Identifying the…